Literature DB >> 11259330

Uptake of teicoplanin by isolated rat hepatocytes: comparison with in vivo hepatic distribution.

R F Reinoso1, B A Telfer, B S Brennan, M Rowland.   

Abstract

Tissue distribution of teicoplanin, a large glycopeptide antibiotic, is slow but at equilibrium its whole body distribution volume is relatively large (Vss = 1.18-2.78 liter/kg), despite a high binding to plasma albumin. In vivo distribution into liver is extensive. Previous in vitro homogenate studies suggest that teicoplanin binds to cell membranes but only enters some cells. This possibility was investigated with isolated hepatocytes incubated for 4 h with [14C]teicoplanin alone and in the presence of additional teicoplanin (1 and 100 microg/ml). Uptake was determined after separating the cells by rapid centrifugation through a dibutyl phthalate layer and assessing viability by the trypan blue exclusion test. Teicoplanin cell uptake curves, initially rapid followed by slower distribution (which agrees with in vivo findings), were adequately described by a closed two-compartment model. Whereas entry into hepatocytes was independent of drug concentration, binding to the cell exterior membrane was concentration-dependent. The equilibrium distribution ratio (Kpu(c) +/- S.D.; 42 +/- 10) was somewhat smaller than estimated in vivo (106 +/- 9), but similar to that reported previously in vitro using liver homogenates (54 +/- 11). Also, the estimated membrane permeability-surface area product was larger in vitro than in vivo (PSu +/- S.D.; 5.5 +/- 2.9 versus 0.74 +/- 0.10 ml/min per whole liver). The most likely explanation for this difference is that in vivo only a small fraction of the total cell surface area is exposed to the perisinusoidal space, where exchange occurs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11259330

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  10 in total

1.  Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  Drug Metab Dispos       Date:  2012-06-04       Impact factor: 3.922

2.  Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.

Authors:  Karelle Ménochet; Kathryn E Kenworthy; J Brian Houston; Aleksandra Galetin
Journal:  J Pharmacol Exp Ther       Date:  2011-12-21       Impact factor: 4.030

Review 3.  Prediction of hepatic clearance in human from in vitro data for successful drug development.

Authors:  Masato Chiba; Yasuyuki Ishii; Yuichi Sugiyama
Journal:  AAPS J       Date:  2009-04-30       Impact factor: 4.009

4.  Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data.

Authors:  Agnès Poirier; Anne-Christine Cascais; Christoph Funk; Thierry Lavé
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-20       Impact factor: 2.745

5.  Hepatic disposition of ximelagatran and its metabolites in pig; prediction of the impact of membrane transporters through a simple disposition model.

Authors:  Erik Sjögren; Ulf Bredberg; Erik Allard; Björn Arvidsson; Jonas Bergquist; Tommy B Andersson; Hans Lennernäs
Journal:  Pharm Res       Date:  2010-02-06       Impact factor: 4.200

6.  Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.

Authors:  Bridget L Morse; Jamus G MacGuire; Anthony M Marino; Yue Zhao; Maxine Fox; Yueping Zhang; Hong Shen; W Griffith Humphreys; Punit Marathe; Yurong Lai
Journal:  AAPS J       Date:  2017-10-10       Impact factor: 4.009

7.  In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.

Authors:  Jennifer E Sager; Sasmita Tripathy; Lauren S L Price; Abhinav Nath; Justine Chang; Alyssa Stephenson-Famy; Nina Isoherranen
Journal:  Biochem Pharmacol       Date:  2016-11-09       Impact factor: 5.858

8.  Pharmacokinetics of teicoplanin in an ICU population of children and infants.

Authors:  John C Lukas; Georgios Karikas; Maria Gazouli; Panagiotis Kalabalikis; Tasos Hatzis; Panos Macheras
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

9.  Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.

Authors:  Priyanka Kulkarni; Kenneth Korzekwa; Swati Nagar
Journal:  J Pharmacol Exp Ther       Date:  2016-07-22       Impact factor: 4.030

10.  Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition.

Authors:  Chie Emoto; Trevor N Johnson; Takaaki Yamada; Hiroshi Yamazaki; Tsuyoshi Fukuda
Journal:  Eur J Clin Pharmacol       Date:  2021-02-01       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.